The clinical and immunological features of alopecia areata following SARS-CoV-2 infection or COVID-19 vaccines

References

• Gilhar A, Etzioni A, Paus R. Alopecia areata. N Engl J Med. 2012;366(16):1515–1525. doi: 10.1056/NEJMra1103442
   PubMed Web of Science ®Google Scholar
• Rajabi F, Drake LA, Senna MM, et al. Alopecia areata: a review of disease pathogenesis. Br J Dermatol. 2018;179(5):1033–1048. doi: 10.1111/bjd.16808
   PubMed Web of Science ®Google Scholar
• Borde A, Åstrand A. Alopecia areata and the gut-the link opens up for novel therapeutic interventions. Expert Opin Ther Targets. 2018;22(6):503–511. doi: 10.1080/14728222.2018.1481504
   PubMed Web of Science ®Google Scholar
• Simakou T, Butcher JP, Reid S, et al. Alopecia areata: a multifactorial autoimmune condition. J Autoimmun. 2019;98:74–85. doi: 10.1016/j.jaut.2018.12.001
   PubMed Web of Science ®Google Scholar
• Talotta R. Do COVID-19 RNA-based vaccines put at risk of immune-mediated diseases? In reply to “potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases”. Clin Immunol. 2021;224:108665. doi: 10.1016/j.clim.2021.108665
   PubMed Web of Science ®Google Scholar
• Richardson CT, Hayden MS, Gilmore ES, et al. Evaluation of the relationship between alopecia areata and viral antigen exposure. Am J Clin Dermatol. 2018;19(1):119–126. doi: 10.1007/s40257-017-0312-y
   PubMed Web of Science ®Google Scholar
• Wraith DC, Goldman M, Lambert PH. Vaccination and autoimmune disease: what is the evidence? Lancet. 2003;362(9396):1659–1666. doi: 10.1016/S0140-6736(03)14802-7
   PubMed Web of Science ®Google Scholar
• Chu CH, Cheng YP, Chan JY. Alopecia areata after vaccination: recurrence with rechallenge. Pediatr Dermatol. 2016;33(3):e218–9. doi: 10.1111/pde.12849
   PubMed Web of Science ®Google Scholar
• Abrantes TF, Artounian KA, Falsey R, et al. Time of onset and duration of post-COVID-19 acute telogen effluvium. J Am Acad Dermatol. 2021;85(4):975–976. doi: 10.1016/j.jaad.2021.07.021
   PubMed Web of Science ®Google Scholar
• Nguyen B, Tosti A. Alopecia in patients with COVID-19: a systematic review and meta-analysis. JAAD Int. 2022;7:67–77. doi: 10.1016/j.jdin.2022.02.006
   PubMedGoogle Scholar
• Rizzetto G, Diotallevi F, Campanati A, et al. Telogen effluvium related to post severe sars-cov-2 infection: clinical aspects and our management experience. Dermatol Ther. 2021;34(1):e14547. doi: 10.1111/dth.14547
   PubMed Web of Science ®Google Scholar
• Perry T 2nd, Rosen H, Pettit C, et al. Pressure-induced alopecia due to proning in COVID-19. Dermatol Ther. 2021;34(2):e14764. doi: 10.1111/dth.14764
   PubMed Web of Science ®Google Scholar
• Aiyegbusi OL, Hughes SE, Turner G, et al. Symptoms, complications and management of long COVID: a review. J R Soc Med. 2021;114(9):428–442. doi: 10.1177/01410768211032850
   PubMed Web of Science ®Google Scholar
• Kim JS, Lee GJ, Jeong CY, et al. Risk of alopecia areata after COVID-19. JAMA Dermatol. 2024. doi: 10.1001/jamadermatol.2023.5559.
   Web of Science ®Google Scholar
• Birkett L, Singh P, Mosahebi A, et al. Possible associations between alopecia areata and COVID-19 vaccination and infection. Aesthet Surg J. 2022;42(11):Np699–np702. doi: 10.1093/asj/sjac165
   PubMed Web of Science ®Google Scholar
• Bardazzi F, Guglielmo A, Abbenante D, et al. New insights into alopecia areata during COVID-19 pandemic: when infection or vaccination could play a role. J Cosmet Dermatol. 2022;21(5):1796–1798. doi: 10.1111/jocd.14864
   PubMed Web of Science ®Google Scholar
• Capalbo A, Giordano D, Gagliostro N, et al. Alopecia areata in a COVID-19 patient: a case report. Dermatol Ther. 2021;34(2):e14685. doi: 10.1111/dth.14685
   PubMed Web of Science ®Google Scholar
• Gallo G, Mastorino L, Tonella L, et al. Alopecia areata after COVID-19 vaccination. Clin Exp Vaccine Res. 2022;11(1):129–132. doi: 10.7774/cevr.2022.11.1.129
   PubMed Web of Science ®Google Scholar
• May Lee M, Bertolani M, Pierobon E, et al. Alopecia areata following COVID-19 vaccination: vaccine-induced autoimmunity? Int J Dermatol. 2022;61(5):634–635. doi: 10.1111/ijd.16113
   PubMed Web of Science ®Google Scholar
• Pastukhova E, Li HO, Brandts-Longtin O, et al. Alopecia areata as a sequela of COVID-19 vaccination: a systematic review. J Cutan Med Surg. 2023;27(1):64–65. doi: 10.1177/12034754221138249
   PubMed Web of Science ®Google Scholar
• Kara Polat A, Oguz Topal I, Karadag AS, et al. The impact of COVID-19 in patients with psoriasis: a multicenter study in Istanbul. Dermatol Ther. 2021;34(1):e14691. doi: 10.1111/dth.14691
   PubMed Web of Science ®Google Scholar
• Berbert Ferreira S, Gavazzoni Dias MFR, Berbert Ferreira R, et al. Rapidly progressive alopecia areata totalis in a COVID-19 patient, unresponsive to tofacitinib. J Eur Acad Dermatol Venereol. 2021;35(7):e411–e412. doi: 10.1111/jdv.17170
   PubMed Web of Science ®Google Scholar
• Essam R, Ehab R, Al-Razzaz R, et al. Alopecia areata after ChAdOx1 nCoV-19 vaccine (Oxford/AstraZeneca): a potential triggering factor? J Cosmet Dermatol. 2021;20(12):3727–3729. doi: 10.1111/jocd.14459
   PubMed Web of Science ®Google Scholar
• Lo A, Mir A, Sami N. Letter in reply: alopecia areata after SARS-CoV-2 vaccination. JAAD Case Rep. 2022;25:25–26. doi: 10.1016/j.jdcr.2022.04.022
   PubMedGoogle Scholar
• Rossi A, Magri F, Michelini S, et al. Recurrence of alopecia areata after COVID-19 vaccination: a report of three cases in Italy. J Cosmet Dermatol. 2021;20(12):3753–3757. doi: 10.1111/jocd.14581
   PubMed Web of Science ®Google Scholar
• Scollan ME, Breneman A, Kinariwalla N, et al. Alopecia areata after SARS-CoV-2 vaccination. JAAD Case Rep. 2022;20:1–5. doi: 10.1016/j.jdcr.2021.11.023
   PubMedGoogle Scholar
• Su HA, Juan CK, Chen YC. Alopecia areata following ChAdOx1 nCoV-19 vaccination (Oxford/AstraZeneca). J Formos Med Assoc. 2022;121(10):2138–2140. doi: 10.1016/j.jfma.2022.03.006
   PubMed Web of Science ®Google Scholar
• Chen CH, Chen YY, Lan CE. Intractable alopecia areata following the second dose of COVID-19 vaccination: report of two cases. Dermatol Ther. 2022;35(9):e15689. doi: 10.1111/dth.15689
   PubMed Web of Science ®Google Scholar
• Nguyen B, Tosti A. Alopecia areata after COVID-19 infection and vaccination: a cross-sectional analysis. J Eur Acad Dermatol Venereol. 2023;37(1):e7–e8. doi: 10.1111/jdv.18491
   PubMed Web of Science ®Google Scholar
• Egawa N, Egawa K, Griffin H, et al. Human papillomaviruses; epithelial tropisms, and the development of Neoplasia. Viruses. 2015;7(7):3863–3890. doi: 10.3390/v7072802
   PubMed Web of Science ®Google Scholar
• Baldini E, Odorisio T, Tuccilli C, et al. Thyroid diseases and skin autoimmunity. Rev Endocr Metab Disord. 2018;19(4):311–323. doi: 10.1007/s11154-018-9450-7
   PubMed Web of Science ®Google Scholar
• Ricciardi A, Ruberto A, García-Hernández MJ, et al. Alopecia areata with comorbid depression: early resolution with combined paroxetine-triamcinolone treatment. J Eur Acad Dermatol Venereol. 2006;20(8):1000–1001. doi: 10.1111/j.1468-3083.2006.01592.x
   PubMed Web of Science ®Google Scholar
• Tassone F, Cappilli S, Antonelli F, et al. Alopecia areata occurring after COVID-19 vaccination: a single-center, cross-sectional study. Vaccines (Basel). 2022;10(9):1467. doi: 10.3390/vaccines10091467
   PubMed Web of Science ®Google Scholar
• Jensen A, Stromme M, Moyassari S, et al. COVID-19 vaccines: considering sex differences in efficacy and safety. Contemp Clin Trials. 2022;115:106700. doi: 10.1016/j.cct.2022.106700
   PubMed Web of Science ®Google Scholar
• Kabashima K, Honda T, Ginhoux F, et al. The immunological anatomy of the skin. Nat Rev Immunol. 2019;19(1):19–30. doi: 10.1038/s41577-018-0084-5
   PubMed Web of Science ®Google Scholar
• Guarnieri G, Bertagna De Marchi L, Marcon A, et al. Relationship between hair shedding and systemic inflammation in COVID-19 pneumonia. Ann Med. 2022;54(1):869–874. doi: 10.1080/07853890.2022.2054026
   PubMed Web of Science ®Google Scholar
• Goren A, Vaño-Galván S, Wambier CG, et al. A preliminary observation: male pattern hair loss among hospitalized COVID-19 patients in Spain - a potential clue to the role of androgens in COVID-19 severity. J Cosmet Dermatol. 2020;19(7):1545–1547. doi: 10.1111/jocd.13443
   PubMed Web of Science ®Google Scholar
• Namazi MR, Ashraf A, Handjani F, et al. Angiotensin converting enzyme activity in alopecia areata. Enzyme Res. 2014;2014:694148. doi: 10.1155/2014/694148
   PubMedGoogle Scholar
• Fahim S, Montazer F, Tohidinik HR, et al. Serum and tissue angiotensin-converting enzyme in patients with alopecia areata. Indian J Dermatol Venereol Leprol. 2019;85(3):295–299. doi: 10.4103/ijdvl.IJDVL_158_17
   PubMed Web of Science ®Google Scholar
• Dotan A, Shoenfeld Y. Perspectives on vaccine induced thrombotic thrombocytopenia. J Autoimmun. 2021;121:102663. doi: 10.1016/j.jaut.2021.102663
   PubMed Web of Science ®Google Scholar
• Tan Y, Tang F. SARS-CoV-2-mediated immune system activation and potential application in immunotherapy. Med Res Rev. 2021;41(2):1167–1194. doi: 10.1002/med.21756
   PubMed Web of Science ®Google Scholar
• Huang WY, Huang YC, Huang KS, et al. Stress-induced premature senescence of dermal papilla cells compromises hair follicle epithelial-mesenchymal interaction. J Dermatol Sci. 2017;86(2):114–122. doi: 10.1016/j.jdermsci.2017.01.003
   PubMed Web of Science ®Google Scholar
• Kanduc D, Shoenfeld Y. Molecular mimicry between SARS-CoV-2 spike glycoprotein and mammalian proteomes: implications for the vaccine. Immunol Res. 2020;68(5):310–313. doi: 10.1007/s12026-020-09152-6
   PubMed Web of Science ®Google Scholar
• Vojdani A, Kharrazian D. Potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases. Clin Immunol. 2020;217:108480. doi: 10.1016/j.clim.2020.108480
   PubMed Web of Science ®Google Scholar
• Pratt CH, King LE Jr., Messenger AG, et al. Alopecia areata. Nat Rev Dis Primers. 2017;3(1):17011. doi: 10.1038/nrdp.2017.11
   PubMedGoogle Scholar
• Paus R, Nickoloff BJ, Ito T. A ‘hairy’ privilege. Trends Immunol. 2005;26(1):32–40. doi: 10.1016/j.it.2004.09.014
   PubMed Web of Science ®Google Scholar
• Becker JC, Varki N, Bröcker EB, et al. Lymphocyte-mediated alopecia in C57BL/6 mice following successful immunotherapy for melanoma. J Invest Dermatol. 1996;107(4):627–632. doi: 10.1111/1523-1747.ep12584237
   PubMed Web of Science ®Google Scholar
• Paus R, Slominski A, Czarnetzki BM. Is alopecia areata an autoimmune-response against melanogenesis-related proteins, exposed by abnormal MHC class I expression in the anagen hair bulb? Yale J Biol Med. 1993;66(6):541–554. doi: 10.1016/0923-1811(93)91068-6
   PubMed Web of Science ®Google Scholar
• Wollina U, Karadağ AS, Rowland-Payne C, et al. Cutaneous signs in COVID-19 patients: a review. Dermatol Ther. 2020;33(5):e13549. doi: 10.1111/dth.13549
   PubMed Web of Science ®Google Scholar
• Seirafianpour F, Sodagar S, Pour Mohammad A, et al. Cutaneous manifestations and considerations in COVID-19 pandemic: a systematic review. Dermatol Ther. 2020;33(6):e13986. doi: 10.1111/dth.13986
   PubMed Web of Science ®Google Scholar
• Cusick MF, Libbey JE, Fujinami RS. Molecular mimicry as a mechanism of autoimmune disease. Clin Rev Allergy Immunol. 2012;42(1):102–111. doi: 10.1007/s12016-011-8294-7
   PubMed Web of Science ®Google Scholar
• Freyschmidt-Paul P, McElwee KJ, Hoffmann R, et al. Interferon-gamma-deficient mice are resistant to the development of alopecia areata. Br J Dermatol. 2006;155(3):515–521. doi: 10.1111/j.1365-2133.2006.07377.x
   PubMed Web of Science ®Google Scholar
• Gilhar A, Kam Y, Assy B, et al. Alopecia areata induced in C3H/HeJ mice by interferon-gamma: evidence for loss of immune privilege. J Invest Dermatol. 2005;124(1):288–289. doi: 10.1111/j.0022-202X.2004.23580.x
   PubMed Web of Science ®Google Scholar
• Jabbari A, Nguyen N, Cerise JE, et al. Treatment of an alopecia areata patient with tofacitinib results in regrowth of hair and changes in serum and skin biomarkers. Exp Dermatol. 2016;25(8):642–643. doi: 10.1111/exd.13060
   PubMed Web of Science ®Google Scholar
• Suárez- Fariñfariñas M, Ungar B, Noda S, et al. Alopecia areata profiling shows TH1, TH2, and IL-23 cytokine activation without parallel TH17/TH22 skewing. J Allergy Clin Immunol. 2015;136(5):1277–1287. doi: 10.1016/j.jaci.2015.06.032
   PubMed Web of Science ®Google Scholar
• Xing L, Dai Z, Jabbari A, et al. Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition. Nat Med. 2014;20(9):1043–1049. doi: 10.1038/nm.3645
   PubMed Web of Science ®Google Scholar
• Agesta N, Zabala R, Díaz-Pérez JL. Alopecia areata during interferon alpha-2b/ribavirin therapy. Dermatology. 2002;205(3):300–301. doi: 10.1159/000065841
   PubMed Web of Science ®Google Scholar
• Kartal ED, Alpat SN, Ozgunes I, et al. Reversible alopecia universalis secondary to PEG-interferon alpha-2b and ribavirin combination therapy in a patient with chronic hepatitis C virus infection. Eur J Gastroenterol Hepatol. 2007;19(9):817–820. doi: 10.1097/MEG.0b013e32818b27e5
   PubMed Web of Science ®Google Scholar
• Musch E, Andus T, Malek M. Induction and maintenance of clinical remission by interferon-beta in patients with steroid-refractory active ulcerative colitis-an open long-term pilot trial. Aliment Pharmacol Ther. 2002;16(7):1233–1239. doi: 10.1046/j.1365-2036.2002.01264.x
   PubMed Web of Science ®Google Scholar
• Radny P, Bauer J, Caroli UM, et al. Alopecia areata induced by adjuvant treatment with alpha-interferon in malignant melanoma? Dermatology. 2004;209(3):249–250. doi: 10.1159/000079904
   PubMed Web of Science ®Google Scholar
• Mihm S, Frese M, Meier V, et al. Interferon type I gene expression in chronic hepatitis C. Lab Invest. 2004;84(9):1148–1159. doi: 10.1038/labinvest.3700135
   PubMed Web of Science ®Google Scholar
• Rossi A, Magri F, Michelini S, et al. New onset of alopecia areata in a patient with SARS-CoV-2 infection: possible pathogenetic correlations? J Cosmet Dermatol. 2021;20(7):2004–2005. doi: 10.1111/jocd.14080
   PubMed Web of Science ®Google Scholar
• Chen Y, Xu Z, Wang P, et al. New-onset autoimmune phenomena post-COVID-19 vaccination. Immunology. 2022;165(4):386–401. doi: 10.1111/imm.13443
   PubMed Web of Science ®Google Scholar
• Geisen UM, Berner DK, Tran F, et al. Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort. Ann Rheum Dis. 2021;80(10):1306–1311. doi: 10.1136/annrheumdis-2021-220272
   PubMed Web of Science ®Google Scholar
• Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271–280.e8. doi: 10.1016/j.cell.2020.02.052
   PubMed Web of Science ®Google Scholar
• Gentile P. Hair loss and telogen effluvium related to COVID-19: the potential implication of adipose-derived mesenchymal stem cells and platelet-rich plasma as regenerative strategies. Int J Mol Sci. 2022;23(16):9116. doi: 10.3390/ijms23169116
   PubMed Web of Science ®Google Scholar
• Wambier CG, Vaño-Galván S, McCoy J, et al. Androgenetic alopecia present in the majority of patients hospitalized with COVID-19: the “gabrin sign”. J Am Acad Dermatol. 2020;83(2):680–682. doi: 10.1016/j.jaad.2020.05.079
   PubMed Web of Science ®Google Scholar
• Wambier CG, Vaño-Galván S, McCoy J, et al. Androgenetic alopecia in COVID-19: compared to age-matched epidemiologic studies and hospital outcomes with or without the gabrin sign. J Am Acad Dermatol. 2020;83(6):e453–e454. doi: 10.1016/j.jaad.2020.07.099
   PubMed Web of Science ®Google Scholar
• Wambier CG. Reply to: “comment on ‘androgenetic alopecia present in the majority of patients hospitalized with COVID-19’”. J Am Acad Dermatol. 2021;84(1):e53–e54. doi: 10.1016/j.jaad.2020.08.088
   PubMed Web of Science ®Google Scholar
• Prie BE, Iosif L, Tivig I, et al. Oxidative stress in androgenetic alopecia. J Med Life. 2016;9(1):79–83.
   PubMedGoogle Scholar
• Hoffmann R, Eicheler W, Wenzel E, et al. Interleukin-1beta-induced inhibition of hair growth in vitro is mediated by cyclic AMP. J Invest Dermatol. 1997;108(1):40–42. doi: 10.1111/1523-1747.ep12285625
   PubMed Web of Science ®Google Scholar
• Jose RJ, Manuel A. COVID-19 cytokine storm: the interplay between inflammation and coagulation. Lancet Respir Med. 2020;8(6):e46–e47. doi: 10.1016/S2213-2600(20)30216-2
   PubMed Web of Science ®Google Scholar
• Tufan A, Avanoğlu Güler A, Matucci-Cerinic M. COVID-19, immune system response, hyperinflammation and repurposing antirheumatic drugs. Turk J Med Sci. 2020;50(Si–1):620–632. doi: 10.3906/sag-2004-168
   PubMed Web of Science ®Google Scholar
• Kato H, Kinoshita K, Saito N, et al. The effects of ischemia and hyperoxygenation on hair growth and cycle. Organogenesis. 2020;16(3):83–94. doi: 10.1080/15476278.2020.1794271
   PubMed Web of Science ®Google Scholar
• Vastarella M, Cantelli M, Nappa P, et al. Black dots in trichoscopy after COVID-19. Can it be telogen effluvium? Dermatol Ther. 2021;34(5):e15053. doi: 10.1111/dth.15053
   PubMed Web of Science ®Google Scholar
• Bulat V, Situm M, Azdajic MD, et al. Potential role of IL-17 blocking agents in the treatment of severe COVID-19? Br J Clin Pharmacol. 2021;87(3):1578–1581. doi: 10.1111/bcp.14437
   PubMed Web of Science ®Google Scholar
• Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8(4):420–422. doi: 10.1016/S2213-2600(20)30076-X
   PubMed Web of Science ®Google Scholar
• Ramot Y, Marzani B, Pinto D, et al. IL-17 inhibition: is it the long-awaited savior for alopecia areata? Arch Dermatol Res. 2018;310(5):383–390. doi: 10.1007/s00403-018-1823-y
   PubMed Web of Science ®Google Scholar
• Bain KA, McDonald E, Moffat F, et al. Alopecia areata is characterized by dysregulation in systemic type 17 and type 2 cytokines, which may contribute to disease-associated psychological morbidity. Br J Dermatol. 2020;182(1):130–137. doi: 10.1111/bjd.18008
   PubMed Web of Science ®Google Scholar
• O’Sullivan JDB, Peters EMJ, Amer Y, et al. The impact of perceived stress on the hair follicle: towards solving a psychoneuroendocrine and neuroimmunological puzzle. Front Neuroendocrinol. 2022;66:101008. doi: 10.1016/j.yfrne.2022.101008
   PubMed Web of Science ®Google Scholar
• Paus R. A neuroendocrinological perspective on human hair follicle pigmentation. Pigment Cell Melanoma Res. 2011;24(1):89–106. doi: 10.1111/j.1755-148X.2010.00808.x
   PubMed Web of Science ®Google Scholar
• Arck PC, Handjiski B, Peters EM, et al. Stress inhibits hair growth in mice by induction of premature catagen development and deleterious perifollicular inflammatory events via neuropeptide substance P-dependent pathways. Am J Pathol. 2003;162(3):803–814. doi: 10.1016/S0002-9440(10)63877-1
   PubMed Web of Science ®Google Scholar
• Alexopoulos A, Chrousos GP. Stress-related skin disorders. Rev Endocr Metab Disord. 2016;17(3):295–304. doi: 10.1007/s11154-016-9367-y
   PubMed Web of Science ®Google Scholar
• Thom E. Stress and the hair growth cycle: cortisol-induced hair growth disruption. J Drugs Dermatol. 2016;15(8):1001–1004.
   PubMed Web of Science ®Google Scholar
• Zhang B, Ma S, Rachmin I, et al. Hyperactivation of sympathetic nerves drives depletion of melanocyte stem cells. Nature. 2020;577(7792):676–681. doi: 10.1038/s41586-020-1935-3
   PubMed Web of Science ®Google Scholar
• Willemsen R, Roseeuw D, Vanderlinden J. Alexithymia and dermatology: the state of the art. Int J Dermatol. 2008;47(9):903–910. doi: 10.1111/j.1365-4632.2008.03726.x
   PubMed Web of Science ®Google Scholar
• Kutlu Ö, Aktaş H, İmren IG, et al. Short-term stress-related increasing cases of alopecia areata during the COVID-19 pandemic. J DermatolTreat. 2022;33(2):1177. doi: 10.1080/09546634.2020.1782820
   Google Scholar
• Goldust M, Agarwal K, Kroumpouzos G, et al. Mental health status of dermatologists during the COVID-19 pandemic: a technology-based therapy. Dermatol Ther. 2020;33(4):e13723. doi: 10.1111/dth.13723
   PubMed Web of Science ®Google Scholar
• García-Hernández MJ, Ruiz-Doblado S, Rodriguez-Pichardo A, et al. Alopecia areata, stress and psychiatric disorders: a review. J Dermatol. 1999;26(10):625–632. doi: 10.1111/j.1346-8138.1999.tb02063.x
   PubMedGoogle Scholar
• Reinke S, Thakur A, Gartlan C, et al. Inflammasome-mediated immunogenicity of clinical and experimental vaccine adjuvants. Vaccines (Basel). 2020;8(3):554. doi: 10.3390/vaccines8030554
   PubMed Web of Science ®Google Scholar
• Li Z, Guo J, Bi L. Role of the NLRP3 inflammasome in autoimmune diseases. Biomed Pharmacother. 2020;130:110542. doi: 10.1016/j.biopha.2020.110542
   PubMed Web of Science ®Google Scholar
• Mauvais-Jarvis F, Klein SL, Levin ER. Estradiol, progesterone, immunomodulation, and COVID-19 outcomes. Endocrinology. 2020;161(9). doi: 10.1210/endocr/bqaa127
   Web of Science ®Google Scholar
• Al-Kuraishy HM, Al-Gareeb AI, Faidah H, et al. The looming effects of estrogen in covid-19: a rocky rollout. Front Nutr. 2021;8:649128. doi: 10.3389/fnut.2021.649128
   PubMed Web of Science ®Google Scholar
• Czech T, Sugihara S, Nishimura Y. Characteristics of hair loss after COVID-19: a systematic scoping review. J Cosmet Dermatol. 2022;21(9):3655–3662. doi: 10.1111/jocd.15218
   PubMed Web of Science ®Google Scholar
• Lovre D, Bateman K, Sherman M, et al. Acute estradiol and progesterone therapy in hospitalised adults to reduce COVID-19 severity: a randomised control trial. BMJ Open. 2021;11(11):e053684. doi: 10.1136/bmjopen-2021-053684
   PubMed Web of Science ®Google Scholar
• Grymowicz M, Rudnicka E, Podfigurna A, et al. Hormonal effects on hair follicles. Int J Mol Sci. 2020;21(15):5342. doi: 10.3390/ijms21155342
   PubMed Web of Science ®Google Scholar
• Gentile P, Garcovich S. Advances in regenerative stem cell therapy in androgenic alopecia and hair loss: wnt pathway, growth-factor, and mesenchymal stem cell signaling impact analysis on cell growth and hair follicle development. Cells. 2019;8(5):466. doi: 10.3390/cells8050466
   PubMed Web of Science ®Google Scholar
• Gentile P, Scioli MG, Bielli A, et al. Platelet-rich plasma and micrografts enriched with autologous human follicle mesenchymal stem cells improve hair re-growth in androgenetic alopecia. biomolecular pathway analysis and clinical evaluation. Biomedicines. 2019;7(2). doi: 10.3390/biomedicines7020027
   PubMed Web of Science ®Google Scholar
• Gentile P. Autologous cellular method using micrografts of human adipose tissue derived follicle stem cells in androgenic alopecia. Int J Mol Sci. 2019;20(14):3446. doi: 10.3390/ijms20143446
   PubMed Web of Science ®Google Scholar
• Gentile P, Garcovich S. Systematic review: the platelet-rich plasma use in female androgenetic alopecia as effective autologous treatment of regenerative plastic surgery. J Plast Reconstr Aesthet Surg. 2022;75(2):850–859. doi: 10.1016/j.bjps.2021.11.004
   PubMed Web of Science ®Google Scholar
• Talei B, Shauly O, Gould D. Platelet rich plasma hybridized adipose transplant (PHAT) for the treatment of hair loss: a case series. Aesthetic Plast Surg. 2021;45(6):2760–2767. doi: 10.1007/s00266-021-02406-0
   PubMedGoogle Scholar
• Wagner C, Griesel M, Mikolajewska A, et al. Systemic corticosteroids for the treatment of COVID-19. Cochrane Database Syst Rev. 2021;8(8):Cd014963. doi: 10.1002/14651858.CD014963
   PubMedGoogle Scholar
• Iorizzo M, Tosti A. Emerging drugs for alopecia areata: JAK inhibitors. Expert Opin Emerg Drugs. 2018;23(1):77–81. doi: 10.1080/14728214.2018.1444750
   PubMed Web of Science ®Google Scholar
• Aşkın Ö, Özkoca D, Uzunçakmak TK, et al. Evaluation of the alopecia areata patients on tofacitinib treatment during the COVID-19 pandemic. Dermatol Ther. 2021;34(2):e14746. doi: 10.1111/dth.14746
   PubMed Web of Science ®Google Scholar
• Xie B, Sun J, Song X. Hair follicle melanocytes initiate autoimmunity in alopecia areata: a trigger point. Clin Rev Allergy Immunol. 2022;63(3):417–430. doi: 10.1007/s12016-022-08954-w
   PubMed Web of Science ®Google Scholar